In trying to develop access to suggested treatments for COVID-19, the World Health Organisation (WHO) has today added Tocilizumab to the list of prequalified treatments of COVID-19. Basically, it is a monoclonal antibody. There is a total of six COVID-19 treatments that have been qualified by the WHO, in which there are three presentations (which includes three vials, each of which is with a different quantity).
Overall, three qualified products have been manufactured by one of the renowned manufacturing companies,’ Roche’, but the listing provides the way for the numerous other companies to step forward to seek WHO prequalification, thereby increasing the number of quality assured products and creating competition leading to potentially lower prices.
The prequalification of these products will also give low and middle-income nations’ authorization of them as treatments for COVID-19.
According to reports, Tocilizumab is a monoclonal antibody that interferes with the Interleukin-6 (IL-6) receptor. Interleukin-6 inflame an inflammatory response & is found in high levels in critically ill patients with the COVID-19.
At the same time, the product has been approved by the WHO primarily for healing arthritis in about 120 nations across the globe.
According to some clinical studies, Tocilizumab has been shown to decrease the chances of death in certain patients with COVID-19, who are ill, are rapidly deteriorating and need urgent oxygen, and have a major provocative response also lowers the patient’s time in the hospital.
At the same time, WHO asks serious patients with severe or critical COVID-19 to take Tocilizumab. A healthcare worker must administer it in an adequately monitored clinical setting and the current standard of care for COVID-19, which includes oxygen and several other medications.
Meanwhile, Tocilizumab is expensive and gives supply to all over the world. It is predicted that the demand for this medicine will be high in the future, and more manufacturers are entering the market; however, prices would go down.
Moreover, WHO and its partners discuss lower prices and improved access in low- and middle-income countries with Roche’s producer.